ResMed Inc. vs Wheaton Precious Metals Corp — how do they compare? ResMed Inc. trades at $225.92 (market cap $31.89B), while Wheaton Precious Metals Corp trades at $138.4 (market cap $61.17B). The key difference: Wheaton Precious Metals Corp is the larger of the two by market cap, and ResMed Inc. pays the higher dividend (1.16%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Wheaton Precious Metals Corp for 66 Days on average.
| RMD | WPM | |
|---|---|---|
Market Cap | $31.89B | $61.17B |
Volume | 618,314 | 1,092,361 |
Sector | Health | Basic Materials |
52-Week High | $277.88 | $165.72 |
52-Week Low | $182.82 | $94.37 |
Typical Hold Time | 51 Days | 66 Days |
Enterprise Value | $31.24B | $63.05B |
Dividend Yield | 1.16% | 0.58% |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
Wheaton Precious Metals (WPM) trades at $133.69, down 2.88% today, amid a bearish technical signal. The stock shows strong fundamentals with record 2025 revenue of $2.31B and net income of $1.47B, driven by high margins and consistent earnings beats. Recent news highlights expansion plans targeting 1.2M ounces by 2030, supported by a robust deal pipeline. Analyst consensus remains strongly bullish with an 80% buy rating and a $164.80 price target, suggesting significant upside from current levels despite near-term technical weakness.
The outlook for WPM is positive due to strong earnings growth, high profitability, and strategic streaming acquisitions. Risks include exposure to gold/silver price volatility, execution of growth targets, and macroeconomic factors like interest rates. With solid cash flow and institutional support, the stock presents a compelling long-term opportunity, though investors should monitor commodity cycles and operational milestones.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →